Gilead Sciences (GILD) said Monday that a phase 3 breast cancer study met its primary endpoint, showing that Trodelvy plus Keytruda "significantly" improved progression-free survival compared with Keytruda and chemotherapy.
The safety profile of the Trodelvy-Keytruda combination also showed consistency with the know safety profile of each agent, Gilead said.
The company said overall survival is a key secondary endpoint and was not mature during the progression-free survival analysis, but there was an early trend in improved overall survival with the combination.
Merck (MRK) and Gilead entered into a collaboration in 2021 to evaluate the Trodelvy-Keytruda combination compared to Keytruda plus chemotherapy in patients with previously untreated, inoperable locally advanced or metastatic triple-negative breast cancer whose tumors express PD-L1, Gilead said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.